Comparing methods to capture circulating tumor cells in metastatic breast or prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a pilot, prospective, single-center study enrolling 36 patients (18 with metastatic breast cancer and 18 with metastatic prostate cancer). Each participant gives blood on one day before initiating a new anti-tumor treatment, and that sample is processed by three different CTC detection techniques: CellSearch®, Parsortix®, and SmartCatch®. The primary aim is to compare the sensitivity of these capture methods for detecting circulating tumor cells. Results will provide comparative data on detection rates across the three platforms in a real-world metastatic setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient with breast cancer (whatever the immunohistochemical subtype: triple-negative, RH+/HER2-negative or HER2-positive) or prostate cancer, multi-metastatic, eligible for a new line of treatment.
2. Patient not yet initiated on a new specific treatment for breast or prostate cancer at inclusion.
3. Age ≥ 18 years and WHO ≤ 2
4. Patient affiliated to Social Security scheme in France.
5. Patient having signed informed consent prior to inclusion in the study and prior to any study-specific procedures.

Exclusion Criteria:

1. Associated pathology(ies) likely to prevent the study procedure from running smoothly
2. Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures stipulated in the study protocol.
3. Patient deprived of liberty or under legal protection (guardianship, legal protection)
4. Patient who has had another solid tumor (excluding carcinoma in situ of the breast or cervix) within 5 years.

Where it's running

• Iuct-O
  Toulouse, France Recruiting

Study contacts

• Study coordinator: Florence DALENC
• Email: Dalenc.florence@iuct-oncopole.fr
• Phone: 05 31 15 51 22

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human imaging test of the GRPR-targeted theranostic pair for advanced breast or prostate cancer

  This early feasibility study tests a GRPR-targeted imaging agent for PET and a low-dose radiopharmaceutical for SPECT in adults with advanced breast or prostate cancer to see if it is safe and can image tumors.

  Recruiting Early Phase 1 Integrated Haematology and Oncology Network · Perth, Western Australia · NCT07608848

• Morning versus evening timing of hormone therapy for metastatic breast and prostate cancer

  This pilot will test whether taking hormone-based cancer drugs in the morning or in the evening works better for people with metastatic breast or prostate cancer.

  Recruiting at 2 sites Phase 4 Ottawa Hospital Research Institute · Kitchener, Ontario and 2 other locations · NCT07252726

• Evaluating the effects of radiotherapy on patients with oligometastatic cancer

  This study is testing how well Stereotactic Ablative Radiotherapy (SABR) works for people with oligometastatic cancer to see if it can help them live longer and feel better.

  Recruiting Institut Investigacio Sanitaria Pere Virgili · Albacete, Albacete and 20 other locations · NCT05933876

• Impact of Exercise and Statins on Cancer Treatment

  This study is testing if doing supervised exercise while taking cancer drugs helps people with metastatic breast, kidney, ovarian, and prostate cancer feel better and respond better to their treatment compared to exercising on their own, and if adding a cholesterol-lowering medication can make it even more effective.

  Recruiting Phase 3 Tampere University Hospital · Tampere, Länsi-Suomi · NCT05796973

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Personalized treatment after endocrine therapy failure in metastatic breast cancer

  The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07895160

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.